Whether to screen for prostate cancer using PSA testing is a difficult decision for many men. Here's the information you need to help them make an educated choice.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
First real-world clinical experience with [Lu]Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer beyond VISION and TheraP criteria.
Eur J Nucl Med Mol Imaging
January 2025
Department of Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands.
Purpose: To report real-world clinical experience with [Lu]Lu-PSMA-I&T targeted radionuclide therapy (TRT) in patients with metastatic castration-resistant prostate cancer (mCRPC) in a single tertiary referral university hospital.
Methods: Patients with mCRPC who were treated with [Lu]Lu-PSMA-I&T TRT as standard of care between February 2022 and August 2023 were included in this retrospective study. Patients were treated with a maximum of six cycles with a fixed activity of 7.
Low baseline IsoPSA Index is associated with a Prolonged Low Risk of Clinically Significant Prostate Cancer Diagnosis in Men with an Elevated PSA.
Urology
January 2025
Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, United States of America.
Objective: To compare the rate of diagnosing clinically significant prostate cancer (csPCa) in men with elevated PSA stratified by baseline IsoPSA Index, thus assessing IsoPSA's intermediate-term predictive ability for csPCa.
Material And Methods: Single-center retrospective review of consecutive patients (n=1578) who underwent IsoPSA testing from November 2016-August 2022. Data dichotomized into patients with low(≤6) and high IsoPSA Indices (>6).
Serum levels of PSA and VEGF2 as the prognosis markers for bone metastasis of prostate cancer: A retrospective study.
Comput Biol Chem
December 2024
Department of Emergency, Wuhan No.6 Hospital(Affiliated Hospital of Jianghan University), No.168, Xianggang Road, Jiangan District, Wuhan, Hubei 430015, China. Electronic address:
Background And Objective: Prostate cancer (PCa) is the second most commonly diagnosed cancer in males, the mechanism of PCa with bone metastasis remains unclear. In this study, we aimed to utilize a retrospective clinical study to evaluate the diagnostic value of bone metastases from PCa and provide reference values for future applications.
Methods: We retrospectively collected a total of 200 samples including 100 PCa patients with bone metastatic and 100 without from June 2019 to August 2021.
Incidence and prognostic implications of PSA persistence and relapse after radical prostatectomy. Population-based study.
J Natl Cancer Inst
January 2025
Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Background: There has been a wide range in incidence of prostate-specific antigen (PSA) persistence and relapse after radical prostatectomy (RP) for prostate cancer (PCa). We aimed to describe incidence and prognostic implications of PSA persistence and relapse.
Methods: Register-based cohort study in Sweden of men diagnosed with PCa between 2007 and 2020 who underwent RP.
Personalized Dynamic Prediction Model for Biopsy Timing in Patients With Prostate Cancer During Active Surveillance.
JAMA Netw Open
January 2025
Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Importance: Active surveillance (AS) for patients with prostate cancer (PC) often includes fixed repeat prostate biopsies that do not account for the varying risk of reclassification to significant disease. Given the invasive nature and potential complications of biopsies, a personalized approach is needed to balance the burden of biopsies with the risk of missing disease progression.
Objective: To develop and externally validate a dynamic model that predicts an individual's risk of PC reclassification during AS.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!